Table 4.

Summary of core evidence for dapoxetine in the treatment of lifelong or acquired premature ejaculation

Outcome measure	Evidence	Implications
Disease-oriented evidence
Increase in intravaginal ejaculatory latency time	Substantial	Dapoxetine is consistently better than placebo at significantly increasing intravaginal ejaculatory latency time
Patient-oriented evidence
Perceived improvement in control over ejaculation	Clear	Dapoxetine is better than placebo at giving men greater perceived control over ejaculation
Greater satisfaction with sexual intercourse	Clear	Dapoxetine gives patients greater satisfaction with intercourse compared with placebo
Less personal distress related to ejaculation	Clear	Distress ratings are significantly reduced with dapoxetine compared with placebo
Less interpersonal difficulty related to ejaculation	Clear	Significantly reduced ratings for interpersonal difficulty with dapoxetine compared with placebo
Improved clinical global impression of change in premature ejaculation	Clear	More patients who received dapoxetine reported a positive change in premature ejaculation compared with those who received placebo
Economic evidence
On-demand use of dapoxetine is more cost-effective than long-term once-daily use of other selective serotonin reuptake inhibitors for treatment of premature ejaculation	No evidence	Health economics studies are needed
On-demand use of dapoxetine is more cost-effective than psychotherapy	No evidence	Health economics studies are needed